Please note: The information displayed on this page might be outdated.
Oculis Pharma: Developer of novel and transformative topical treatments (eye drops) intended for ophthalmic diseases for both back and front of the eye. The company's novel eye-drop treatments are based on its proprietary solubilizing nanoparticle (SNP) technology that improves both the ability to formulate drugs as eye drops and their bioavailability in the eye tissues including both the front and the back of the eye, enabling hospitals to provide clients with technological advancement in ocular drug delivery.
Phase l or ll
Ophthalmology, Rare Disease
EPFL Innovation Park Building C
Company Participants at European Biotech Investor Day 2020
- Riad Sherif, CEO